Byram H. Ozer
Hematology Oncology | Hematology | Neurology
1365 Clifton Road Northeast
BldgC
Atlanta, GA 30322
BldgC
Atlanta, GA 30322
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.
Journal: medRxiv : the preprint server for health sciences
Published: July 03, 2026
Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801).
Journal: AJNR. American journal of neuroradiology
Published: February 19, 2026
Clinical experience with tovorafenib in adults with treatment-refractory high- and low-grade gliomas.
Journal: Neuro-oncology practice
Published: December 29, 2025
CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas.
Journal: Neuro-oncology advances
Published: August 04, 2025
Molecular, histologic, and clinical characterization of methylation class pleomorphic xanthoastrocytoma: An analysis of 469 tumors.
Journal: Neuro-oncology advances
Published: July 30, 2025
Case Report: Molecular diagnostics and clinical courses of two adult spinal pilocytic astrocytoma long-term survivors with GTF2I::BRAF fusion.
Journal: Frontiers in oncology
Published: July 21, 2025
Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas.
Journal: Neuro-oncology
Published: July 14, 2025
Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.
Journal: Neuro-oncology advances
Published: June 24, 2025
Implications of sociodemographic and clinical factors on symptom burden: Age-specific survivorship care in the primary central nervous system tumor population.
Journal: Neuro-oncology practice
Published: June 09, 2025
Glioblastoma-enriched glycosphingolipids modulate the function of human iNKT cells.
Journal: Neuro-oncology
Published: May 28, 2025
Imipridones and Dopamine Receptor Antagonism in the Therapeutic Management of Gliomas.
Journal: Advances in oncology
Published: June 13, 2024
Last Updated: 09/26/2026